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ABSTRACT

Protein aggregates, which can result in cellular toxicity, are found in the brains of people
afflicted with neurodegenerative diseases. One of the proteins found to aggregate is
Tau, a protein that stabilizes microtubules in neuronal cells. Based on its amino acid
sequence, Tau is likely to be N-terminally acetylated by the complex NatA, which is
responsible for the acetylation of a majority of proteins with this post-translational
modification. Mutations in the NatA complex result in a variety of pleiotropic detrimental
phenotypes, showing that acetylation is a crucial modification for many proteins. Without
the presence of NatA – and therefore without acetylation – Tau may be more prone to
aggregation and toxicity. By expressing Tau in yeast strains with and without the
presence of NatA, the possible effects of acetylation or lack thereof can be determined
by examining protein expression and aggregation within the cells by SDS-PAGE and
SDD-AGE. Initial results indicate that Tau aggregates within these yeast cells although
the nature and effect of the aggregates is still being determined. This project has
allowed for the creation of a system by which Tau aggregates can be examined in vivo.
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Neurodegenerative Diseases
Neurodegenerative diseases are disorders which affect the vertebrate nervous system;
they have been known to cause cognitive, behavioral, and motor function which progresses to
eventual incapacitation1.

Many symptoms of neurodegenerative diseases (ND) overlap with

psychiatric symptoms, particularly in the earlier phases of ND; this can lead to problems with
misdiagnoses and ineffectual treatments2.

Proper diagnosis and treatment of ND is critical,

especially as the numbers of people living with ND increase; it is expected that by 2050 there
will be 18.5 million people living with ND2. It is therefore crucial to further investigate the
underlying mechanisms that are responsible for disease onset and progression in the hopes of
finding potential therapies and targets.
Neurodegeneration occurs in many forms, and although symptoms often overlap, there
are many distinct disorders. The most well-known neurodegenerative disorder is Alzheimer’s
disease, although that only accounts for about 50-70% of dementia cases; the remaining cases
of dementia are generally attributed to vascular dementia, frontotemporal lobar degeneration,
corticobasal degeneration, progressive supranuclear palsy, and dementia with Lewy bodies3. In
addition, there are other neurodegenerative disorders that are not typically associated with
dementia but rather with other symptoms, such as progressive non-fluent aphasia, amyotrophic
lateral sclerosis, Huntington disease, and Parkinson’s disease2,4,5. Certain disorders, such as
corticobasal degeneration and progressive supranuclear palsy, can result in early motor
problems, while others such as Alzheimer’s disease and some subtypes of frontotemporal lobar
degeneration present only with personality and behavioral changes at the onset3. As previously
mentioned, this can frequently result in misdiagnoses, especially in younger patients with earlyonset conditions2,3.
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In many cases of neurodegeneration, misfolded proteins aggregate within the central
nervous system and spread to new regions, increasing clinical symptoms as the damage
spreads1.

Synapses between neurons may falter, and communication between neural

pathways is affected1. The different protein aggregates may be localized to certain regions of
the brain, which may account for variation in symptoms between disorders1. Multiple proteins
have been linked to aggregation correlating with neurodegenerative disease, including βamyloid, TDP-43, α-synuclein, and tau.
Many disorders can be categorized as synucleinopathies or tauopathies5.

These

characterizations are based off of the accumulation of α-synuclein or Tau aggregates in the
nervous system, respectively, although co-localization of these proteins has been noted6. αsynuclein is a 140-amino acid protein typically found in the axon terminals of neurons; it plays a
role in synaptic function6,7. The structure can be divided into three main regions: the N-terminal
region, the hydrophobic region, which likely forms a beta sheet, and the acidic C-terminal
region8. α-synuclein has been found localized in the nucleus and cytosol as well as associated
with the membrane9. Synucleinopathies, which can be thought of as a form of protein-misfolding
disorders, typically contain α-synuclein in intracellular inclusions known as Lewy bodies7,9.
Lewy bodies are characteristic in Parkinson’s disease, one of the most well-known
synucleinopathies, as well as dementia with Lewy bodies, the second most common form of
dementia7. Lewy bodies can be found in many regions of the central nervous system, including
the substantia nigra, locus ceruleus, nucleus basalis, hypothalamus, cerebral cortex, and cranial
nerve motor nuclei11.
α-synuclein is encoded by the gene SNCA, and mutations within this gene have been
linked with Parkinson’s disease, likely due to amino acid substitutions or conformational
changes within α-synuclein resulting from the mutation11.

These gene mutations are not

common and only account for about 1% of cases, but it is also possible that variants within this
gene increase the risk of Parkinson’s even if they do not directly cause it11.

SNCA gene

triplication and duplication has also been seen in cases of familial Parkinson’s; it has been
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suggested that overexpression of the gene may be a factor in these patients11.

The potential

for toxicity due to overexpression was shown in a yeast model as well; increasing the levels of
α-synuclein twofold resulted in cytoplasmic inclusions and cell death11. It has also been
suggested that different variants of the SNCA promoter may be associated with increased
susceptibility to Parkinson’s11.
Microtubule-Associated Protein Tau
Like α-synuclein, Tau is found in neuronal cells; it is a microtubule-associated protein
which promotes microtubule polymerization and stability of polymerized microtubules12.

Six

different forms of Tau exist in the adult human brain, ranging from 352 to 441 amino acids and
produced via alternative splicing12. The isoforms differ based on the presence or absence of
29- or 58-amino acid sequences (N) near the N-terminus of the protein, and whether or not they
have three or four tandem repeats (R) near the C-terminus12. The full-length form of the protein
is 2N/4R, but 0N/3R, 0N/4R, 1N/3R, 1N/4R, and 2N/3R are all expressed within the central
nervous system in adults as well, although only the shortest 3R isoform of Tau is seen in fetal
neurons12,13.

4R Tau has been shown to promote microtubule assembly around three times

more than 3R Tau14.

In addition, granule cells and pyramidal cells within the human

hippocampus have differing amounts of 3R and 4R Tau expression; differing degrees of
microtubule polymerization and assembly may be unique within varying cell types, suggesting a
reason for the differing isoforms14.
It has been previously suggested that some mutations resulting in frontotemporal
dementia with Parkinsonism cause increased levels of 4R Tau compared with 3R Tau13. Both
3R and 4R Tau are capable of promoting microtubule polymerization; however, 4R Tau is
capable of significantly stabilizing microtubules to a greater extent, suppressing shortening rates
and reducing the length shortened overall13. An increase in the levels of 4R Tau may potentially
shift microtubule dynamics within the cell; a specific ratio of 4R to 3R may be needed in order to
keep the microtubule dynamics within the narrow range necessary for functionality and prevent
polymerization from occurring too quickly or slowly13. Changes in these microtubule dynamics
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within the cell may affect the cell’s capability to function.

Proper microtubule function is

necessary for maintenance of cellular morphology and intracellular transport, both of which are
crucial for neuronal cell health13.
In addition, mutations in the Tau protein can reduce its binding affinity for microtubules;
G272V, P301L, V336M,

and R401W mutants of Tau all showed reduced affinity for microtubule

binding and reduced capability to facilitate microtubule polymerization15. Impairing the proper
function of Tau, even if the ratio of 4R to 3R remains the same, could also negatively affect the
neuronal cells.
The hallmark of neurodegenerative diseases classified as tauopathies is the formation of
Tau aggregates known as neurofibrillary tangles16.
aggregates is hyperphosphorylated16.

In many cases, the Tau found in these

In normal adult neuronal cells, the phosphorylation of

Tau is highly regulated by a variety of protein kinases and phosphatases16. The phosphorylation
of Tau plays a role in Tau-microtubule interactions and is suggested to serve as a negative
regulator, decreasing the ability of Tau to bind to the microtubule16,17.

In addition,

phosphorylation may affect the ability of Tau to bind to regulatory proteins16. The Tau found in
fetal neurons is also hyperphosphorylated15,16. It is possible that in tauopathies, neuronal cells
respond to some stressor by attempting to return to this initial proliferative phase, at least
partially16.
Hyperphosphorylation is strongly implicated in Tau aggregation; one theory suggests
that Tau aggregates via its microtubule-binding repeats, but the basic regions near these
repeats, and the acidic C-region segment, inhibit Tau-Tau interaction18.

Phosphorylation of

these regions neutralize these domains and allow interaction18. Aggregation of Tau proceeds by
monomeric Tau proteins associating with each other and forming dimers; a conformational
change then results in larger oligomers19. Multiple studies suggest that Tau oligomers may be
more cytotoxic than larger aggregates, which appear as filaments in which a portion of each Tau
protein adopts a beta-sheet conformation; the beta-sheets stack in parallel19,20. In the earlier
stages of aggregation, Tau oligomers are not ubiquitinated, but ubiquitination - a process which
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allows for degradation of potentially toxic protein species - occurs during the transition from
oligomers to filamentous aggregates; it is possible that an abundance of hyperphosphorylated
Tau exceeds the proteasome’s capacity, and the formation of aggregates occurs as a way to
shift the Tau into a more stable form19.

In addition, it has been theorized that certain post-

translationally modified forms of Tau - such as hyperphosphorylated Tau - are directly toxic even
before their formation into aggregates, and the formation of aggregates is an attempt to
sequester cytotoxic species of protein20.
In Alzheimer’s disease patients, the Tau present in neurofibrillary tangles is often
truncated at the C-terminus, suggesting another post-translational modification that may be
relevant to propensity to aggregation, at least in this specific disease21. This truncation may be
linked to exposure to amyloid precursor protein (APP, cleaved to amyloid-beta, Aβ), which
suggests a potential link between their pathologies; unlike frontotemporal dementia with
Parkinsonism, in which only Tau aggregates are present, Alzheimer’s disease includes both
neurofibrillary tangles of Tau protein and extracellular amyloid plaques composed of Aβ21.
Although previously thought of as independent pathologies, amyloid plaques and neurofibrillary
tangles have been linked by recent studies showing that exposure to Aβ increases
neurofibrillary tangles in a murine model21. As it has been also suggested that amyloid plaques
occur prior to Tau pathology, it is possible that the presence of Aβ plaques result in changes
within the cell that alter the modification state and conformation of Tau, leading to aggregation22.
This also implies that Aβ aggregation may be the trigger for Alzheimer’s disease, while Tau
aggregation may occur as a downstream effect22.
It is also possible that interactions between α-synuclein and Tau may play a role in the
formation of aggregates. Co-occurrence of α-synuclein and Tau inclusions has been previously
noted in human ND patients23. Normal α-synuclein is capable of self-polymerization, while this
is less likely to occur with Tau; α-synuclein can potentially act as a cofactor to initiate Tau
fibrillization23. Tau fibrillization in the presence of α-synuclein likely results from polymers of αsynuclein that act as chaperones to produce a conformational change23. In addition, rates of α-
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synuclein polymerization were shown to increase significantly in the presence of Tau,
suggesting that Tau is capable of promoting α-synuclein fibrillization as well23.
Mechanisms already correlated with Tau aggregation include the previously-discussed
post-translational modifications (PTMs): phosphorylation and truncation. As any modification to
a protein has the capability to affect its structure - and therefore its function - it is reasonable to
assume that other modifications may also play a role in the propensity of Tau to aggregate
within the cells. One such modification, which has not been widely studied in this regard, is Nterminal acetylation.
N-Terminal Acetylation
Discovered over fifty years ago, N-terminal acetylation - the addition of an acetyl group
to the N-terminus of a protein, thus changing the positive charge present on the N-terminus to a
neutral charge - is one of the most common protein modifications in eukaryotic organisms,
occurring in 85% of proteins in humans and 50% of proteins in yeast24. The difference in these
numbers suggests that acetylation patterns differ between species although the fundamental
process remains the same, and indeed, this was shown to be true. For instance, about half of
human proteins with methionine-lysine termini are acetylated, but yeast proteins with this
terminus are not acetylated25.
N-terminal acetylation is performed by one of six different N-terminal acetyltransferase
(NAT) complexes - NatA through NatF - and the sequence of amino acids present in the
protein’s N-terminus determines which NAT is responsible for acetylation of that protein24. For a
majority of proteins, it is only the first and second amino acid of the sequence that are
responsible for affecting acetylation25.

Serine and alanine termini are most likely to be

acetylated; methionine, glycine, and threonine are the next most likely, and 95% of acetylated
proteins have one of these amino acids at their end terminus26.
NatA is the most active NAT complex, responsible for acetylating a majority of proteins specifically those with Ser-, Ala-, Thr-, Gly-, Cys-, and Val- termini exposed by cleavage of the
initial methionine25.

In contrast, NatB and NatC acetylate proteins with initial methionine
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residues; NatB acetylates proteins with methionine followed by asparagine, aspartate, or
glutamate while NatC acetylates those with methionine followed by isoleucine, leucine,
phenylalanine, or tryptophan27. NatD is specialized for acetylating the N-terminus of histone
proteins, and NatE acetylates proteins that have leucine at position 2 and proline at position 429.
NatF is responsible for acetylating proteins with initial methionine residues, specifically those
followed by lysine, valine, alanine, or a second methionine28.
Given that cleavage of the initial methionine residue is a common post-translational
modification in eukaryotic proteins, it follows that the NAT complex - NatA - responsible for
acetylating proteins with this cleaved methionine is therefore responsible for acetylating the
most protein. NatA is composed of three subunits; in yeast, the main subunits are Nat1 and
Ard124.

Ard1 is the catalytic subunit, while Nat1 is responsible for anchoring Ard1 to the

ribosome, allowing co-translational modification25.

Both of these subunits are required for

proper function of NatA, and the over-expression of both genes is necessary for overproduction
of the NatA complex29.

Over-expression of only one subunit does not result in any significant

increase in acetyltransferase activity, but when both are over-expressed, activity can increase
up to 20-fold30. In the same way, null mutants of Nat1, null mutants of Ard1, and double null
mutants (Nat1/Ard1) in Saccharomyces cerevisiae all show very similar phenotypes,
showcasing how both subunits are necessary for the proper function of the final protein30.
Since NAT complexes are responsible for acetylating proteins with a variety of functions,
lacking one or more NAT complexes leads to defects in a variety of cellular processes and
pathways which can be completely unrelated to one another30. In Saccharomyces cerevisiae,
loss of N-terminal acetylation, caused by knockout of Nat1 and/or Ard1, results in several
phenotypes including slow growth, inability to sporulate, and failure to enter G0 when
necessary30. Decreased mating, increased sensitivity to heat shock, and increased sensitivity to
sodium chloride were also observed in mutant Saccharomyces cerevisiae with reduced Nterminal acetylation28. Despite these defects, these strains remain viable, suggesting that N-
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terminal acetylation, although clearly important to the function of many proteins and the overall
health of the cell, may not be completely necessary in all normally-acetylated proteins29.
In humans, however, disturbances to N-terminal acetylation are more prominent and
more likely to result in lethality. Ogden syndrome, an X-linked disorder, correlates to a mutation
in the gene which encodes the catalytic subunit of the NatA complex31.
cranial abnormalities,

Symptoms include

hypotonia, and cardiac problems, which eventually lead to death during

infancy32. Deregulation of NatA expression is also linked to the development of tumors32. The
human homolog of the Saccharomyces cerevisiae Nat1 unit, NATH, is found over-expressed in
papillary thyroid carcinomas and is found in dividing tissues, suggesting that it might play a role
in a cell’s ability to proliferate33.

Increased protein synthesis would be necessary in rapidly-

growing tumor cells, which would then result in the acetylation of more proteins overall.
The severity of effects in humans is likely due to the increased amount of proteins that
are N-terminally acetylated in humans as opposed to Saccharomyces cerevisiae, as well as the
increased complexity of the processes involved in a multicellular organism like Homo sapiens
compared with a single-celled organism such as Saccharomyces cerevisiae.
The higher amount of proteins acetylated in humans rather than yeast could partially be
due to a larger amount of NatB substrates; 19% of acetylated human proteins are acetylated by
NatB, while only 9.5% of acetylated yeast proteins utilize NatB25. In addition, a larger amount of
amino acid sequences in humans can result in N-terminal acetylation - for instance, human
proteins with the N-terminal sequence Met-Lys are acetylated while yeast-proteins with this Nterminus are not25.

The increase in acetylation in multicellular eukaryotes such as humans is

also likely due to the presence of NatF, which is not present in the single-celled eukaryotes such
as S. cerevisiae28. Divergence of both the NAT complexes themselves and their human protein
targets could be responsible for the increased percentage of N-terminally acetylated proteins in
humans25.
Although it is clear that the pleiotropic phenotypes seen with a lack of acetylation is likely
caused by the wide variety of proteins which receive this modification, and disruption to this
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modification results in the disruption of various other cellular pathways, it is not currently known
what the true function of acetylation is.

It is apparently an irreversible process34.

N-terminal

acetylation occurs when the nascent polypeptide chain is ~50 amino acids long, and can be
considered a co-translational modification24. As eukaryotic proteins fold co-translationally, it is
reasonable to assume that N-terminal acetylation may play a role in protein folding as well24.
One study shows evidence that N-terminal acetylation can be responsible for the
creation of degradation signals in proteins with this modification34.

Initially this seems

impossible, since so many proteins, especially in higher eukaryotes, are acetylated, and many
of them last a reasonable length of time before being degraded.

However, other processes

could also play a role. N-terminal acetylation may form degradation signals, but if the protein
associates with chaperone proteins, forms a complex, or folds in a way that blocks the Nterminus from associating with ubiquitin ligase or any other enzymes responsible for
degradation, it may block the degradation signal from being recognized34. On the other hand, if
the protein is slow to properly fold or form a complex, the N-terminal degradation signal may
remain open to the cellular environment and become recognized by ubiquitin ligase or others,
resulting in quicker degradation; this suggests that N-terminal acetylation may potentially play a
role in regulation and quality control34.
As expected from this potential role as a degradation signal, N-terminal acetylation does
not protect against degradation by the proteasome35. It is possible that protease resistance,
folding, and thermal stability may be impaired in proteins without acetylation, but there is little
evidence for these direct effects35. It was shown in alpha-synuclein that N-terminal acetylation
increases stabilization and helical propensity as well as decreasing rates of aggregation, likely
due to secondary structure changes that resulted from the change from an N-terminal positive
charge in the non-acetylated form to a neutral charge36.

Acetylation increases helicity in

proteins, and this effect on the protein’s structure will cause varying effects depending on the
particular protein and its function37.
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It has also been shown that N-terminal acetylation is far more common in cytosolic
proteins - those that remain in the cytoplasm - than those which are sent to the endoplasmic
reticulum for secretion out of the cell27. Acetylation appears to inhibit protein targeting to the
ER; most secretory proteins are unmodified, and the presence of acetylation decreases the
chances of a protein being translocated and secreted out of the cell27. It is possible, therefore,
that the presence of acetylation is a marker that results in a protein staying within the cytoplasm
instead of being moved to the ER27.
It has also been shown that lack of acetylation can be beneficial for certain proteins; in
human hemoglobin, for instance, the acetylated form results in a reduced affinity of hemoglobin
to oxygen38.

It has also been suggested that some proteins are only acetylated because their

amino acid sequences are favorable to the NAT complex, and the protein does not actually
require acetylation for its proper function38.

This could occur because evolution results in

certain sequences being conserved for other reasons - for instance, a serine at position 2 of the
amino acid sequence promotes phosphorylation and initial methionine cleavage as well as Nterminal acetylation, but it is entirely possible that the protein only requires one of these for its
function38.
Acetylation depends upon acetyl-CoA levels, since it is an essential cofactor in the
process of N-terminal acetylation; this provides a clear link between cellular metabolism and
acetylation39. Inhibiting acetyl-CoA production in cells has resulted in lower levels of N-terminal
acetylation as well as lower levels of apoptotic sensitivity39. It is therefore clear that acetylation
is a widespread process that affects many aspects of life within the cell, and its exact
functionality likely cannot be narrowed down to just one factor.
In the same way, even the NAT complexes themselves may have multiple functions.
New evidence suggests that NAT complexes are also capable of acting as
propionyltransferases, transferring a propionyl group from propionyl-CoA to the N-terminus of a
protein40. Propionylation occurs at a lower rate than acetylation, which could be at least partially
explained by the lower concentration of propionyl-CoA in cells compared to that of acetyl-CoA40.
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It is a naturally occurring process; NAT complexes are capable of propionylating proteins both in
vitro and in vivo40. Currently, the modifications of acetylation and propionylation are not linked,
but this shows how the NAT complexes may have a role in multiple cellular pathways.
Prevention of acetylation obviously occurs, as previously discussed, when one or more
of the NAT complexes is not present or otherwise nonfunctional, but this is not the only way to
block acetylation. Presence of a proline at the first or second position of a polypeptide chain
prevents acetylation; this is known as the (X)PX rule38. Proteins with a proline at the second
position remain non-acetylated even when the primary amino acid is serine or alanine, two
amino acids which generally result in N-terminal acetylation by NatA38. Knowing this (X)PX rule
allows for manipulation of amino acid sequences to prevent a protein’s acetylation, allowing it to
be studied for potential changes in stability or any other functions.

There is tentative

experimental evidence for proline residues being acetylated in yeast, although this has not been
proven; if it is true, it could potentially be another difference in acetylation between multicellular
and unicellular eukaryotes38.
Saccharomyces cerevisiae as a Model System
S. cerevisiae is a valuable tool as a model organism. Although a unicellular eukaryote, it
is still capable of carrying out many of the basic cellular processes - such as acetylation - which
are important to life; unlike prokaryotes, it is capable of many post-translational modifications41.
Practically speaking, yeast are straightforward to work with, inexpensive, and have a short
generation time42. Yeast are consistently used to produce foreign proteins, which allows this
organism to be the model system for many different fields of research41.
Yeast are used as a model to study neurodegenerative diseases42.

Although these

diseases themselves may only be present in some multicellular organisms, the processes which
occur in affected organisms can also be observed in a unicellular system.

Studying

tauopathies, for instance, is entirely capable in S. cerevisiae; expression of Tau in yeast does
not result in a negative phenotype42. This provides a perfect basis for studies of Tau; if the
protein alone does not result in a notable stress response of any kind, experimental
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manipulations can more easily be performed.

One such manipulation which has been

previously studied is the co-expression of Tau and α-synuclein; as co-localization has been
noted in clinical samples, the association continues to be investigated42.
α-synuclein itself has caused growth delays when expressed in S. cerevisiae; when it
was co-expressed with Tau, the growth delays seen were comparable to that of when αsynuclein was expressed alone, with no additive effect resulting from the inclusion of Tau42. As
previously stated, expression of Tau on its own did not result in arrested growth42.

The

presence of α-synuclein affected solubility of Tau, resulting in a higher fraction of insoluble
(aggregated) Tau protein than what was seen in cells with Tau alone42. α-synuclein was also
found to increase the levels of phosphorylated Tau42. It has been previously suggested that αsynuclein forms a complex of sorts with GSK3β (the kinase which mediates phosphorylation)
and Tau which results in increased phosphorylation; this finding suggests that it is capable of
forming a similar complex with a yeast orthologue of GSK3β42,43. These results do show that
Tau is phosphorylated and is capable of aggregating within S. cerevisiae although no negative
phenotypes were directly associated with increased levels of Tau phosphorylation and
aggregation; this result could potentially just be explained by the difference between yeast cells
and human neurons42.
Tau phosphorylation or hyperphosphorylation is not only observed in the presence of αsynuclein; human protein Tau expressed in yeast on its own, without any other foreign proteins,
is capable of aggregating and being phosphorylated44. In S. cerevisiae, this process is
controlled by yeast kinases; two suggested to be particularly important are Mds1 and Pho85,
which are the orthologues of the human kinases GSK3β and cdk5, respectively44.

Tau

expressed in yeast strains lacking Pho85 were shown to have increased amounts of
phosphorylation and aggregation, suggesting that Pho85 - and therefore possibly cdk5 in
neuronal cells - acts as a negative regulator of these processes44. Absence of Mds1, on the
other hand, resulted in decreased amounts of hyperphosphorylated Tau44.

Both 3R and 4R

isoforms of Tau were used in the study, and although both were phosphorylated, there was a
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marked difference in that 3R was not seen to undergo extensive aggregation while 4R was44.
Overall the finding that the 4R isoforms aggregate more readily than the 3R isoforms implies
that the extra microtubule-binding domain may potentially be relevant in the formation of
aggregates44. That being said, binding of Tau to yeast microtubules has not been previously
noted, suggesting that it may be the structure of this domain, rather than its function, which is
particularly important in aggregate formation44. Because Tau is not currently known to bind to S.
cerevisiae microtubules, studies regarding microtubule binding must be done outside the cell;
that being said, the Tau protein used in said studies can be expressed and purified from yeast
cells, reducing the need to use the more expensive, complicated, and time-consuming
mammalian cell cultures. Tau-4R purified from yeast retains its ability to bind to microtubules
and has been noted to do so in vitro45.
Phosphorylation was decreased in the absence of mds1, and ability to bind increased;
likewise, phosphorylation increased in the absence of the negative regulator Pho85 and ability
to bind to microtubules decreased45. Hyperphosphorylated Tau isolated from neuronal cells of
Alzheimer’s disease patients also was shown not to have normal interactions with microtubules,
confirming this finding45. A mutant isoform of Tau (P301L) was also used in this study, and it
was shown to aggregate on the microtubules themselves45. Mutations in the gene encoding for
Tau can lead to a variety of mutant Tau forms, which may contribute to disease by being more
prone to aggregation45.

The hyperphosphorylated form disturbed the overall structure and

organization of the microtubules but did not appear to form large clusters on them; it was
assumed that this form resulted in smaller aggregates45.
Another factor potentially affecting the behavior of Tau protein is oxidative stress, in
which reactive oxygen species or free radicals are formed within the cell46.

It has been

previously suggested that oxidative stress may play a role in tauopathies, playing a role in the
formation of neurofibrillary tangles in conjunction with hyperphosphorylation46.

Treatment of

yeast cells with ferrous sulfate resulted in increased levels of insoluble Tau in wild-type cells46.
Both mutant Tau forms and the wild-type 2N-4R isoform consistently showed these increased
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levels of aggregation; however, it was noted that the mutant forms showed significantly higher
levels of aggregation than that of the the 2N-4R isoform, suggesting that the mutants are more
susceptible to aggregation induced via oxidative stress46. This experiment was also performed
on cells lacking the Pho85 kinase, although the effect was not as noteworthy as that of the wildtype cells46. Analysis by Western blot suggested that Tau - or at least the 2N-4R isoform - could
actually be dephosphorylated under oxidative stress conditions46. Overall, this suggests that
oxidative stress acts in parallel to phosphorylation to cause aggregation46. Iron ions have also
been found in Lewy bodies, and addition of iron ions to yeast cells expressing alpha-synuclein
showed increased aggregation, suggesting that oxidative stress may play a role in many
different forms of neurodegenerative disease, and this can also be easily replicated in this yeast
model47.
It is clear, therefore, that multiple factors likely correlate with increased aggregation.
Phosphorylation has been previously linked with acetylation; however, the effects of other posttranslational modifications have not been extensively examined. N-terminal acetylation is the
most common protein modification24, yet it has not been considered as a potential factor which
could affect aggregation. S. cerevisiae is capable of N-terminally acetylating proteins, and has
previously been characterized as a useful model system for protein expression in vivo41. This
project has involved expressing Tau in S. cerevisiae with the goal of creating a system with
which to examine the effects of acetylation on Tau in vivo.
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MATERIALS AND METHODS
Yeast growth
Unless otherwise stated, all cultures were grown in YPD media at 30°C, and a roller drum or
shaking platform was used to allow for aeration.

Heat shock treatments were performed by

growing the yeast at 37°C for at least four hours.
Yeast strains
74D-694 (psi- WT) cells were used as a parent strain and served as the wild-type control for all
experiments, as well as providing the wild-type background for integrant strains. 74D-694 cells
with the the nat3 subunit of NatB knocked out served as the parent strain for all ∆NatB
integrants mentioned. 64D-694 cells with the mak3 subunit of NatC knocked out served as the
parent strain for all ∆NatC integrants mentioned. ∆NatA strains had both the Ard1 and Nat1
subunits of ∆NatA knocked out.
Plasmids
pYX212-Tau (2N4R) with +URA selection marker
pRS304-GPD (Tau-GFP) with +TRP selection marker
pRS304-GPD (Tau-A2P) with +TRP selection marker
pRS304-GPD (Tau-A2P-GFP) with +TRP selection marker
Integration of plasmids into yeast genome
Each plasmid (Tau, Tau-A2P, Tau-GFP, Tau A2P-GFP) was linearized by restriction digest with
the enzyme Bsu36I prior to integration. 10mL of cells were spun down and washed before
resuspension in 50 uL of 100 mM LiAc prior to a 15-minute 30°C incubation period. The cell
suspension was then added to the solution of linearized plasmid and 300 uL of PEG-LiAc was
added prior to another incubation period of 30 minutes at 30°C. Heat shock at 42°C for 20
minutes then followed. Cells were pelleted and resuspended in sterile water before plating on
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selective media (SD-URA for Tau integrants, SD-TRP for Tau-A2P, Tau-GFP, or Tau A2P-GFP
integrants).

SDS-PAGE
2.5 ODs of yeast cells were lysed via NaOH lysis and resulting lysates were resuspended in 50
uL of SDS sample buffer (2.25 mM BME, 1.3 mM SDS, 10 mM glycerol, 0.07% bromophenol
blue, 12% 1 M Tris-HCl 6.8). 8% polyacrylamide gels allowed for resolving of proteins, which
were then transferred onto a PVDF membrane and visualized via standard Western blot
procedure using anti-Tau and anti-GPD antibodies.
SDD-AGE
40 ODs of cells were spun down and washed, keeping everything on ice. Standard glass bead
lysis was used to lyse the cells. Samples were then added to SDD-AGE sample buffer (24%
1M Tris-HCl 6.8, 15% glycerol, 3 mM SDS, 3 mM bromophenol blue) and incubated at 30°C for
5 minutes. Lysates were loaded onto a 1.25% agarose gel containing 0.0002% SDS in a Trisglycine buffer. 1x LRB was used as a running buffer. Gels were resolved for roughly 40 minutes
at 160V and transferred onto a PVDF membrane at 20V for 3 hours. Visualization was done
using standard Western blot procedure with anti-Tau antibody.
Microscopy
A wet mount of 10 uL of exponentially growing culture was prepared, and excess light exposure
on the slide was minimized by keeping the slide in an enclosed container until visualization.
Slides were visualized via fluorescence microscopy at 40x magnification.
Oxidative stress treatment
100 mL cultures were treated with 1M FeSO4 for two hours before centrifugation and lysis in
order to cause oxidative stress.
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RESULTS
Expression of the Microtubule-Associated Protein Tau in Saccharomyces cerevisiae
As Tau is a protein found in mammalian neurons, our model system of S. cerevisiae are
not capable of endogenously producing this protein of interest1.

Standard LiAc/PEG yeast

transformation protocol is useful but has to be consistently repeated since future generations of
cells do not retain the plasmid. As a result, the transformation protocol was adapted to include
the linearization of the Tau plasmid via restriction enzyme (Fig. 1) to allow for insertion directly
into the yeast genome to ensure that the production of Tau remained constant from one
generation to the next.
Although S. cerevisiae do not endogenously produce Tau, they are capable of posttranslational modifications such as N-terminal acetylation, which is performed by one of several
N-acetyltransferase (NAT) complexes2. Based on its amino acid sequence, Tau is predicted to
be acetylated by NatA.

In order to determine the effect of acetylation or lack thereof, four

strains were chosen for integration with the Tau plasmid: wild-type, ∆NatA, ∆NatB, and ∆NatC.
The Tau plasmid also contained a marker for growth on selective media (in this case, +URA)
which ensured that only cells which successfully took up the plasmid would grow on SD-URA
plates.

As each integration resulted in multiple colonies, several colonies were selected for

screening in order to determine the most efficient production of Tau in each strain. The colonies
were restruck on a selective plate and lysed in order to examine expression of Tau, which was
visualized via Western blot (Figure 2A, 2B). These Western blots were used to determine the
best integrant colony which was done by examining the blot for the most effective protein
expression (that is, the darkest band), and this process was repeated for all four strains.
Following this process, the selected integrant colonies were frozen down as new strains
of yeast for use in future experiments. Expression of Tau was again confirmed by Western blot
of the four new strains and their parent strains, which lack Tau (Figure 3). In order to examine
whether any growth differences were qualitatively observed, a spot plate of the parent strains
and the Tau strains was performed (Figure 4A). The presence of Tau did not appear to inhibit
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growth; conversely, in some cases, the strains with Tau seemed to have increased growth
compared with the wild-type or ∆Nat knockout parent strain.
Production of Tau-A2P Strain
Although the ∆NatA+Tau strain created is assumed to have unacetylated Tau, it is also
true that this strain has a large amount of other proteins which are typically acetylated. Yeast
strains lacking NAT complexes typically show phenotypic deficits in temperature resistance,
growth, mating, and other variables3,4.

Because of this, it could potentially be difficult to

determine whether any differences seen between the WT+Tau and ∆NatA+Tau strain are solely
due to the acetylation status of Tau, as opposed to a downstream effect based on the complete
loss of the NatA complex. To account for this, a version of Tau containing a substitution at the
second position (alanine to proline) was also utilized. A proline at the second position blocks
acetylation5, so by integrating this version of the Tau plasmid into wild-type yeast, we could have
unacetylated Tau in a completely healthy background. The same protocol for integration into the
yeast genome was followed; the selective marker here was +TRP so the successful integrants
would grow on SD-TRP media. Integrant colonies were screened by selection of the colony
with the best protein expression, analyzed via Western blot (Figure 5A). The Tau-A2P plasmid
was also integrated into ∆NatA cells (Figure 5B). Expression of Tau was again confirmed for all
of the Tau-producing strains via Western blot (Figure 5C). Growth differences were examined
via spot test (Figure 4B). There did not appear to be any differences between the growth of
strains producing Tau and the wild-type strain (Figure 4B).
Visualization of Tau Aggregation in S.cerevisiae by SDD-AGE
Although SDS-PAGE is a very useful tool for determining whether or not a protein is
expressed, this method is not particularly conducive to examining aggregation; aggregates do
not typically survive the denaturing conditions, and are also typically too large for the pores of a
polyacrylamide gel. In order to visualize Tau aggregates in S. cerevisiae, we utilized SDD-AGE
(Semi-Denaturing Detergent Agarose Gel Electrophoresis) which has previously been utilized to
examine other forms of aggregates. SDD-AGE has previously been used for visualization of
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Sup35 prion aggregates in yeast, but has never before been used to visualize Tau aggregates.
In order to determine whether or not this method would be sufficient for visualization of Tau
aggregates, Sup35-HA prion aggregates were utilized as a control. As seen in Figure 6, the
Sup35-HA aggregates were higher on the gel than the Tau aggregates; this indicates the Tau
aggregates are smaller than Sup35 aggregates, but a quantitative comparison is not possible
due to the current lack of a proper standard or ladder for this method.
As this method requires a large OD of cells, we next wanted to determine whether or not
it was feasible to use frozen pellets or if this method always had to be started from fresh pellets
(Figure 7). WT+Tau cells were flash-frozen via liquid nitrogen and placed in a -80°C cooler.
Another sample of ∆NatC+Tau cells were placed in the freezer without flash-freezing.

As

comparison, a fresh sample of WT+Tau cells was taken, and then all three samples were lysed
and run on the gel. The lanes of both frozen samples had no visible signal on the Western blot,
suggesting that some aspect of the freeze-thaw cycle disrupts aggregation, and therefore
freezing down pellets is not adaptable to this method.

In the future, it may be useful to

determine whether or not the total proteome is disrupted by the freeze-thaw cycle, or whether
this may be a Tau-specific effect.
Next, multiple strains of Tau-producing yeast were examined via this method to
determine Tau aggregation between strains with and without acetylation (Figure 8, Figure 9).
Although the strains of different aggregates are not identical, they are consistently similar in
size. Small differences may be noted, such as a slight shift up in Tau-A2P (Figure 9) but without
a ladder there is no way to quantify this kind of minor shift.
In addition to directly examining the differences between strains, we were also aiming to
examine the potential differences in aggregates when exposed to cellular stress. In an attempt
to examine this, a sample of WT+Tau yeast was treated for two hours with 1M FeSO4, which
results in oxidative stress for the cells6. This sample and a control sample of WT+Tau yeast
which had not received the oxidative stress treatment were examined via SDD-AGE (Figure 10).
A slight shift upward may be apparent in the 2-hr treatment lanes, but as before with the
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different strains, small shifts are difficult to quantify or fully claim without a standard. Future
experiments will involve examining the different strains when under some form of cellular stress
to see whether there is a noticeable difference between the aggregates of different strains when
exposed to the same stressor.
Examination of Cellular Stress by Microscopy
Microscopy is often used as a tool to visually examine differences between cells.

In

particular, green fluorescent protein (GFP) can be a valuable tool for examining localization and
therefore aggregation, since GFP is easily visible in cells with the aid of a fluorescent
microscope. In order to determine whether differences between localization and/or amount of
GFP-tagged protein can be visualized using this method, strains containing GFP fused to heat
shock protein 104 were examined. Two different strains - one [PSI+] and one [psi-] - were
examined with and without the presence of a heat shock treatment in order to qualitatively
determine if a difference was visible in the amount and localization of Hsp104-GFP (Figure 11).
In both cases the heat shock treatment resulted in brighter patches of Hsp104-GFP, although it
is important to note that this was qualitative and no quantification or cell-counting was
performed to determine significance.
Following this determination, the psi- strain containing Hsp104-GFP was transformed
with either the empty vector or the Tau plasmid and again examined under the microscope to
examine whether or not the presence of Tau within the cells appeared to be a version of cellular
stress analogous to heat shock which would result in increased levels of this chaperone protein
(Figure 12). Qualitatively, it did appear that for at least some of the cells, the presence of Tau
was a stressor which increased in increased levels of chaperone proteins, which were seen as
brighter green cells.
Production and Examination of Strains Containing Tau-GFP
Since examining cellular stress by chaperone expression does not directly examine the
effects of Tau aggregates, new strains were created which had a Tau-GFP construct.

Once

again, the plasmid was linearized and integrated directly into the yeast genome, and several

30

integrant colonies were selected for screening from each strain (Figure 13A). The Tau-GFP
plasmid was integrated into wild-type, ∆NatA, and ∆NatC cells.

In addition, a construct

containing A2P-Tau-GFP was also integrated into WT and ∆NatA yeast for the same purpose as
the creation of the initial Tau-A2P strain; any differences seen could then be assumed to be the
result of the acetylation status of Tau rather than downstream effects of lacking the NatA
complex completely.

Expression of Tau for all of the GFP strains was again confirmed via

Western blot (Figure 13B).

Growth differences were visualized via spot test (Figure 14).

Expression of Tau-GFP was confirmed via fluorescence microscopy (Figure 15).
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Selection marker

Plasmid
Restriction enzyme
Yeast chromosome

Figure 1: Schematic explaining the integration of genetic material into the
Saccharomyces cerevisiae genome. LiAc transformation of yeast cells was adapted to
include the linearization of the plasmid of interest in order to insert into the chromosome.

32

Isolates 1

2

3

4

5

6

7

8

9

A.
WT+Tau

Isolates

1

2

3

4

5

6

7

8

B.
∆NatA+Tau

Figure 2: Examples of isolate screening Western blots. Following integration, colonies
which successfully grew on selective media were isolated and restruck on a second plate. Each
of those colonies was then lysed, and the lysates ran on SDS-PAGE. A: Expression of Tau in
wild-type yeast integrated with the linearized Tau plasmid. B: Expression of Tau in ∆NatA yeast
integrated with the linearized Tau plasmid.
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Tau

GPD

Figure 3: Initial Tau-producing strains and parent strains. Tau expression visualized via
Western blot with anti-Tau antibody and anti-GPD load control.
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WT
∆NatA
∆NatB
∆NatC
WT+Tau
∆NatA+Tau
∆NatB+Tau
∆NatC+Tau
A.

WT
WT+Tau-A2P
WT+TauA2P-GFP
∆NatA+Tau-A2P
∆NatA+TauA2P-GFP

B.

Figure 4: Spot test showing parent strains and mutant strains. A: Parent strains and initial
Tau-producing strains. B: Strains containing Tau-A2P. Spot tests generated by diluting a
saturated overnight culture by a factor of 1:10 for each successive spot.
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Isolate 7
Isolate 7
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Isolate 6
Isolate 6

Isolate 5

Isolate 3
Isolate 3

Isolate 4

Isolate 2
Isolate 2

Isolate 1

WT+Tau

Isolate 8

Isolate 5

Isolate 4

Isolate 1

∆NatA+Tau

A.

∆NatC+Tau

∆NatB+Tau

WT+Tau-A2P

∆NatA+Tau

WT+Tau

WT

B.

C.

Figure 5: Expression of Tau-A2P. A: Expression of Tau in integrant colonies of WT+Tau-A2P,
compared to the previously-created WT+Tau strain, visualized via Western blot with anti-Tau
antibody. B: Expression of Tau in integrant colonies of ∆NatA+Tau-A2P, visualized via Western
blot with anti-Tau antibody. C. Western blot of Tau-producing strains with GPD load control.
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WT+Tau

Sup35-HA

Sup35-HA

WT+Tau

Sup35-HA

Sup35-HA

WT

Figure 6: SDD-AGE of Tau aggregates andSup35-HA prion aggregates. Sup35-HA prion
aggregates were run as a control, since Tau has never been visualized by this method
previously. Anti-Tau antibody was used as the primary, and anti-HA was added to the secondary
antibody solution.
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∆NatC+Tau frozen

WT+Tau flash frozen

WT+Tau fresh

∆NatC+Tau frozen

WT+Tau flash frozen

WT+Tau fresh

WT

Figure 7: SDD-AGE of fresh and frozen pellets. Visualized via Western blot using an anti-Tau
antibody.
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∆NatC+Tau

∆NatA+Tau

WT+Tau

WT

Figure 8: SDD-AGE comparing the Tau aggregates of three Tau-producing strains.
Visualized via Western blot using an anti-Tau antibody.
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∆NatC+Tau

WT+A2P-Tau

∆NatA+Tau

WT+Tau

WT

Figure 9: SDD-AGE showing WT Tau compared with ∆NatA, A2P, and ∆NatC. Visualized
via Western blot using an anti-Tau antibody.
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WT+Tau (2-hr treatment)

WT+Tau

WT

WT+Tau (2-hr treatment)

WT+Tau

WT

Figure 10: Effects of oxidative stress on WT+Tau yeast. Effects of oxidative stress and/or
heat stress will be examined in the different strains. Visualized via Western blot, using an antiTau antibody.
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PSI+

PSI+HS

psi-

psi- HS

Figure 11: Qualitative microscopy of Hsp104-GFP cells. Microscopy, with the aid of GFPtagging proteins, can be another method to examine cellular stress. Cells with GFP-tagged
heat shock protein 104 (Hsp104) were heat shocked to qualitatively examine differences in GFP
expression and determine whether this is an optimal method to potentially examine cell stress.
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empty
vector

Tau
plasmid

Figure 12: Qualitative microscopy of psi- Hsp104-GFP cells either transformed with the
Tau plasmid or an empty vector.
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∆NatA+Tau-A2PGFP

WT+Tau-A2P-GFP
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WT+Tau-GFP

WT+Tau
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WT
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B.
GPD

Figure 13: Tau expression of Tau-GFP strains. A: Sample isolate Western blot showing the
expression of Tau-GFP in the WT+Tau-GFP integrant colonies compared to WT+Tau. B:
Expression of Tau-GFP in the final strains, visualized via Western blot.
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WT

WT+Tau-GFP
∆NatA+Tau-GFP

∆NatC+Tau-GFP

Figure 14: Spot test of GFP strains. Saturated overnight cultures were diluted 1:10 for each
successive spot.
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WT+Tau-GFP

∆NatA+Tau-GFP

Figure 15: Representative sample images of Tau-GFP strains under the microscope.
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DISCUSSION
Although N-terminal acetylation is a very common post-translational modification, its
eﬀects on the protein Tau have not been properly examined. The amino acid sequence of Tau
suggests that it is a suitable candidate for acetylation by the NatA complex; an alanine residue
exposed by methionine cleavage, as seen in Tau, is a common target for NatA1,2. In addition,
acetylation of Tau’s N-terminus has been observed in both Tau from Alzheimer’s patients and
normal Tau2. It is reasonable to predict that if this modification is indeed present, then it likely
has some eﬀect on the protein. N-terminal acetylation changes the positive N-terminus to a
neutral charge by the addition of an acetyl group3. Any change in charge could potentially
aﬀect the propensity of a protein to interact with other molecules within the cell; it could also
aﬀect the way in which the protein folds. It is important to examine all factors which may play a
role in Tau’s structure and function; changes in any of these pathways could contribute to
aggregation and tauopathy. Other modifications such has hyperphosphorylation have
previously been correlated with increased aggregation; although these studies do not discuss
acetylation directly, they do show how changes to the protein’s structure can aﬀect stability
and function.
S. cerevisiae provide a useful model organism for protein expression; their eukaryotic
structure provides at least a basal similarity to human cells4. They endogenously contain the
NAT complexes responsible for acetylation as well as the molecular machinery to perform other
post-translational modifications4. S. cerevisiae have been previously utilized as a model to
study neurodegenerative disease, and expression of Tau in yeast is eﬃcient and does not
cause negative phenotypes5. Based on amino acid sequence, Tau should be acetylated in
wild-type yeast. Expressing Tau in S. cerevisiae allows for experiments in vivo which can
examine changes to acetylation status. By examining the diﬀerence in results between the
strain containing Tau-A2P and the strain which lacks NatA entirely, for instance, it can be
determined whether the potential eﬀects seen are due to the eﬀect of Tau specifically lacking
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acetylation or due to an overall reduction of acetylated proteins within the cell and disruption of
other cellular pathways that may result in downstream eﬀects on Tau.
The formation of Tau aggregates is heavily implicated in neurodegenerative disease6.
Any method which can characterize or examine Tau aggregates could provide insight into
factors aﬀecting aggregation as well as allow for characterization of these aggregates. This
project showcases the first occurrence of SDD-AGE being utilized to examine Tau aggregation.
SDD-AGE has been previously utilized to examine other protein aggregates, such as Sup35
prion aggregates from S. cerevisiae, but it has not been previously used as a method to
examine Tau. Our results show that this method is a viable option for visualizing Tau
aggregates. Although no notable diﬀerences have been seen in aggregate sizes between the
strains, future work will attempt to examine the eﬀect of diﬀerent treatments and how the
strains respond. It could be possible that under normal conditions, unacetylated and
acetylated Tau aggregate at similar rates, but with the addition of a further stressor, changes in
aggregation dynamics may be visible. Increased aggregation has been noted under various
experimental conditions, including mutations in the Tau protein7, oxidative stress7, and the
presence of α-synuclein5. This suggests that aggregation is aﬀected by multiple factors which
may work in parallel with one another, and disease conditions may not be directly caused by
any one on its own. It is therefore crucial to examine the interplay of diﬀerent conditions. Heat
and oxidative stress are typically utilized in yeast models to examine cell stress, and these will
likely be the first conditions examined further. Preliminary work was done with an oxidative
stress treatment (Figure 10); these results are not fully conclusive but may indicate that
oxidative stress does slightly increase aggregate size in WT+Tau yeast, suggesting that this
treatment may be a viable method for aﬀecting aggregation rate/amount. Further directions
will include utilizing some form of oxidative stress treatment like this on all of the diﬀerent yeast
strains as well as testing heat stress to determine whether that could also diﬀerentially aﬀect
aggregate size between strains.
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These diﬀerences in aggregate size will also be examined via microscopy. Preliminary
data suggests that fluorescence microscopy is a viable tool for examining localization of GFPtagged proteins in S. cerevisiae cells; although none of the data collected has been quantified,
this again suggests that this method could be utilized in the future to examine diﬀerences
between strains. The same sort of conditions which will likely be examined via SDD-AGE - that
is, heat stress and oxidative stress - will also be used to treat cells prior to microscopy in order
to potentially visualize the diﬀerences in aggregation within the cells themselves. Ideally, the
results gained from microscopy and the results gained from SDD-AGE could together provide a
more complete picture of Tau aggregation within the strains. Fluorescence microscopy could
also provide insight into localization of aggregates within cells, particularly if it diﬀers among
conditions.
So far, this project has established that S. cerevisiae is a useful model for examining Tau
aggregation. Tau has been constitutively been expressed in multiple strains with and without
acetylation, and although precise eﬀects of acetylation have yet to be conclusively determined,
it is safe to say that this system provides a valuable basis for further experiments regarding
acetylation’s eﬀects. We have shown that Tau aggregates within yeast strains and these
aggregates can be visualized by way of SDD-AGE, and GFP-tagged Tau aggregates can be
visualized via fluorescence microscopy. The results shown here have laid the groundwork,
allowing for future experiments which aim to determine the eﬀect of acetylation or lack thereof
on aggregation of Tau. As any modification to a protein can cause structural changes, which
can therefore impact its interactions with other proteins, it is important to examine all of these
modifications to Tau in the hopes of finding ways to potentially reduce aggregation.
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